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Abstract Estrogen is atheroprotective and a high-affinity
ligand for both known estrogen receptors, ERα and ERβ.
However, the role of the ERα in early-stage atherosclerosis
has not been directly investigated and is incompletely
understood. ERα-deficient (ERα−/−)a n dw i l d - t y p e
(ERα+/+) female mice consuming an atherogenic diet were
studied concurrent with estrogen replacement to distinguish
the actions of 17β-estradiol (E2) from those of ERα on the
development of early atherosclerotic lesions. Mice were
ovariectomized and implanted with subcutaneous slow-
release pellets designed to deliver 6 or 8μg/day of
exogenous 17β-estradiol (E2)f o rap e r i o do fu pt o
4 months. Ovariectomized mice (OVX) with placebo pellets
(E2-deficient controls) were compared to mice with endog-
enous E2 (intact ovaries) and exogenous E2. Aortas were
analyzed for lesion area, number, and distribution. Lipid and
hormone levels were also determined. Compared to OVX,
early lesion development was significantly (p<0.001) atten-
uated by E2 with 55–64% reduction in lesion area by
endogenous E2 and >90% reduction by exogenous E2.
Compared to OVX, a decline in lesion number (2- to
4-fold) and lesser predilection (~4-fold) of lesion formation
in the proximal aorta also occurred with E2. Lesion size,
development, number, and distribution inversely correlat-
ed with circulating plasma E2 levels. However, atheropro-
tection was independent of ERα status, and E2 athero-
protection in both genotypes was not explained by changes
in plasma lipid levels (total cholesterol, triglyceride, and
high-density lipoprotein cholesterol). The ERα is not
essential for endogenous/exogenous E2-mediated protection
against early-stage atherosclerosis. These observations have
potentially significant implications for understanding the
molecular and cellular mechanisms and timing of estrogen
action in different estrogen receptor (ER) deletion murine
models of atherosclerosis, as well as implications to human
studies of ER polymorphisms and lipid metabolism. Our
findings may contribute to future improved clinical decision-
making concerning the use of hormone therapy.
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Introduction
Coronary heart disease is relatively rare in premenopausal
women compared to postmenopausal women or men.
After menopause, the sex protection in women decreases,
and cardiovascular risk parameters are adversely impacted
[1]. Pathogenic consequences of menopause and sex
differences in disease prevalence are attributed to differ-
ences in estrogen levels supplied to cardiovascular tissues.
Estradiol (17β-estradiol, E2) atheroprotection has been
documented in many animal models of atherosclerosis [2–
5], including murine models with targeted mutations
( r e v i e w e di n[ 6]).
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e-mail: avillablanca@ucdavis.eduIn humans, observational epidemiological studies strong-
ly support an atheroprotective role for endogenous E2 [7],
largely attributed to reductions in low-density lipoprotein
(LDL) and increases in high-density lipoprotein (HDL)
cholesterol [8, 9], antioxidant actions [10, 11], and a direct
biological effect on cardiovascular tissue [12–14]. In
contrast, clinical trials have failed to confirm the benefits
of combined or unopposed estrogen reported by earlier
observational studies [15–17]. The hypothesis that hormone
therapy is an effective preventive measure for coronary
heart disease has been challenged by these trials, perhaps in
part due to the inclusion of postmenopausal women with
subclinical coronary artery plaque. The weight of the
evidence indicates that older women and those with
subclinical or overt coronary heart disease should not take
hormone therapy. However, timing of initiation of hormone
therapy in relation to menopause onset and age might
reduce coronary risk over time, presumably by affording
atheroprotection prior to the onset of established vascular
disease [18]. In addition, factors including the method of
administration, dose, and duration of use of exogenous
hormone may also be relevant. Nonetheless, the overall
clinical utility of hormone therapy for atheroprevention
remains controversial and complex.
Estrogen’s long-term effects are generally ascribed to
transcriptional modulation of target genes through estrogen
receptors (ERs) [19]. Two ERs, ERα (ESR1) and ERβ
(ESR2), have been characterized [20, 21]. They are
encoded on two separate genes (ESR1 and ESR2), are
distinct functionally and structurally, and have overlapping
though not identical tissue expression patterns [21–23].
Functional estrogen receptors are expressed in vascular
endothelial cells [24], smooth muscle cells [25, 26], and
macrophages [27]. Normal coronary arteries of premeno-
pausal women demonstrate normal ER expression, whereas
in atherosclerotic vessels of postmenopausal women, ERs
are downregulated [28]. Thus, changes in expression of
ERs accompany atherogenesis, though the direction and
magnitude of the association needs clarification.
In humans and rodents, both ERs may mediate protec-
tion against vascular injury [25, 29]. However, the
individual contribution of sex steroid hormones and their
cognate receptors to the atherosclerosis and its progression
remains poorly understood. In LDL-receptor (LDL-R) and
apolipoprotein (Apo) E-deficient mice, ERα is a major
mediator of E2’s atheroprotective effects on advanced
atherosclerotic lesions [30–33]. However, studies to distin-
guish the atheroprotective effects of E2 from those of ERα
in the development of early atherosclerosis and examine the
mechanism of E2 protection in fatty-steak formation are
limited. In comparing the effects of E2 treatment on
spontaneous development of atherosclerotic lesions in
ApoE−/− mice (with or without the ERα), the major
atheroprotective effect of E2 was substantially abrogated
in mice lacking both ApoE and ERα [33]. However, some
of the protective effects of E2 appeared to be ERα
independent.
Thus, there is continued need to define the individual
contribution(s) of estrogen and estrogen receptors to
atherosclerosis, the stage(s) of atherosclerosis when estro-
gen is atheroprotective, and the stage-specific mechanism
(s) involved in vasculoprotection. The goal of this study
was to directly examine the action of the ERα in E2-
mediated atheroprotection, using a murine model of early-
stage atherosclerosis (fatty streaks) deficient for the ERα,i n
order to directly examine the action of the ERα in early E2-
mediated atheroprotection, identify the individual contribu-
tion(s) of estrogen and/or the ERα to early atherogenesis,
and address mechanisms of E2 protection in early vascular
disease. The study design permitted us to evaluate three
potential individual and/or interrelated mechanisms for
atheroprotection in early-onset disease: [1]1 7β-estradiol
(E2), [2] the estrogen receptor-alpha (ERα), and [3] serum
lipids.
Materials and Methods
All experiments were performed in compliance with the
National Institutes of Health (NIH) Guidelines and in
accordance with protocols approved by the Animal Care
and Use Committee of the University of California, Davis.
Generation and Use of Mice Mice heterozygous for the
ERα gene (ERα+/−), obtained from Dr. Dennis Lubahn
(University of Missouri) and mated to yield a breeding
colony and progeny lacking the ERα gene (ERα−/−), and
wild-type littermate controls having intact ERα (ERα+/+)
were used. The correct genotype was confirmed by
polymerase chain reaction (PCR) amplification of ge-
nomic DNA. Tail DNA from progeny of heterozygous
matings was genotyped as previously described [34]u s i n g
DNeasy spin columns (Qiagen kit) per the manufacturer’s
instructions. PCR amplification was used to distinguish
homozygous mutants from heterozygotes and wild-type
animals. Primers used to amplify products specific for the
wild-type gene and disrupted ERα gene were synthesized
as custom primers (Life Technologies). Primer sequences
for presence of the targeted ERα gene in homozygous
mutants (a 649-bp fragment only) and animals with the
normal wild-type gene (a 239-bp fragment only) were as
follows:
ERα−/− (KO) forward 5′ TGAATGAACTGCAG
GACGAG 3′ and reverse 5′ AATATCACGGGTAGC
CAACG 3′
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CAT 3′ and reverse 5′ AGACCTGTAGAAGGCGG
GAG 3′
Mice were housed in a temperature-, 12 h light-, and
humidity-controlled environment in a dedicated pathogen-
free barrier facility at the University of California, Davis.
ERα gene deletion mice have a mixed genetic background
from strains 129/J and C57BL/6 J, an atherosclerosis-
susceptible strain. They are infertile but otherwise pheno-
typically normal [34]. They do not produce a fully
functional ERα and have no demonstrable full-length
wild-type ERα protein [34]. However, the disrupting neo-
sequence used to generate the knockout results in a variant
ERα protein (not the full-length ERα wild-type protein)
contained an internal deletion of a portion of the N-terminal
region of the receptor. This alternative ERα protein has
residual low-level, high-affinity, estradiol-binding activity
[35, 36] but, importantly, lacks the specificity to be from
either ERα or ERβ (Liu and Lubahn, unpublished data).
Atherogenesis Model and Experimental Design Experimen-
tal animals were weaned at 4 weeks. To manipulate
estrogen status, age-matched ERα−/− and ERα+/+ female
mice were castrated at 6–7 weeks of age by bilateral
ovariectomy (OVX) under anesthesia (2.5% Avertin). OVX
mice were then implanted with subcutaneous hormone
pellets (Innovative Research, Toledo, OH, USA) designed
for slow release of 6μg/day of exogenous E2 as 17β-
estradiol (exogenous E2-6; n=19 and n=18 for ERα−/− and
ERα+/+ mice, respectively), or 8μg/day of exogenous E2
as 17β-estradiol (exogenous E2-8; n=21 and n=20 for
ERα−/− and ERα+/+ mice, respectively) for a total of up to
4 months. The 6-μg/day E2 dose was chosen based on
analogous models indicating that this dosage attains blood
levels at peak estrus necessary to lower plasma lipids and
plaque size [30–32]. The 8-μg/day E2 dose was chosen to
assess the dose–response of exogenous E2 and the impact
of higher E2 dose and levels on atheroprotection. OVX
ERα−/− (n=22) and ERα+/+ (n=20) mice implanted with
placebo vehicle pellets served as E2-deficient controls. In
addition, ERα−/− (n=18) and ERα+/+ (n=19) female mice
with ovaries left intact served as an additional study group
for evaluating the comparative vascular effect of endoge-
nous E
2. Intact ERα-deficient females have generally been
excluded from prior studies due to plasma E2 levels that are
higher than wild-type mice as a consequence of their
estrogen insensitivity [37]. However, we chose to include
these mice to evaluate the effect of higher endogenous
estrogen in our model.
To induce atherosclerotic lesions, mice were fed a high-
fat, high-cholesterol, atherogenic diet [38, 39], herein
referred to as the atherogenic diet (Purina; 15% wt/wt butter
fat, 1.25% wt/wt cholesterol, and 0.5% cholic acid) for
4 months starting 1 week after surgical recovery from OVX.
The diet was formulated to be phytoestrogen-free. Aortas
(five to eight from each genotype) were sampled for lesion
formation at baseline (age 6–7 weeks, immediately before
cholesterol feeding), and after 2 and 4 months on the
atherogenic diet.
Aortic Atherosclerotic Lesion Analysis To determine extent
of characteristics and extent of atherosclerotic lesions in
aortas and determine any regional differences in athero-
sclerosis susceptibility, we adapted and optimized previ-
ously published and reproducible methods for atheroma
quantification [40], as previously described [41]. Oil Red
O-stained (Sigma) cryosections (10μm thick) defined and
characterized neutral lipid in the vessel wall, permitting
histological assessment and quantitative evaluation of
lesions in three artery segment locations (proximal seg-
ment=proximal aortic arch; mid segment=suprarenal aorta;
distal segment=infrarenal aorta proximal to the iliac
bifurcation). Fatty streaks (herein, early lesions) were
analyzed for area, location, and quantity by direct imaging
(Olympus BX-40 Microscope, Olympus DP11 Camera with
64 MB smart media chip). Quantitative total lesion area and
mean lesion size (μm
2±SEM) for each early lesion was
determined morphometrically (Image Pro Plus, version
4.1). Qualitative morphological assessment of lesion com-
plexity used, as parameters, extent of subintimal lipid
deposition and ORO staining and absence or presence of
foam cells. Wall thickness, disruption of vessel wall
architecture, and distortion of nuclear proliferation were
not assessed as they were not part of the early-lesion
pathology in the study’s early-lesion model. For each
mouse, a total of 36 cryosections (discarding every other
section) were obtained from the proximal, mid, and distal
aortic segments for extensive sampling of a total of
>2,100μm per aorta.
Measurement of Uterine Weight The entire uterus was
collected at baseline and 2 and 4 months to assess in vivo
exposure to estradiol. Serosal fat was removed, the uterus
divided from the utero-tubal junction bilaterally, transected
at the junction of the uterine body and cervix, and uterine
wet weight recorded relative to body weight.
Quantification of Plasma Estradiol Plasma levels of free
17β-estradiolwere determinedinstudymiceatbaselineand2
and 4 months on the atherogenic diet. Assays were performed
in duplicate by enzyme immunoassay (Cayman Chemical,
Ann Arbor, MI, USA) on nonpooled plasma samples.
Quantification of Plasma Lipids Plasma lipid levels were
measured in study mice at baseline and 2 and 4 months on
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(TG) with Triglyceride (INT) Reagent (Sigma); high-
density lipoprotein cholesterol (HDL-C) with a colorimetric
reagent kit (Wako) after precipitating the ApoB-containing
particles; and total cholesterol (TC) using a GM7 Analox
Analyzer (Analox). All assays were performed in duplicate
on nonpooled plasma samples.
Statistical Analysis Lesion area and lesion number were
quantified by calculating the total lesion area and total
number of lesions, respectively, in each of the 36 aortic
sections for each mouse aorta. Comparisons between study
groups were made using Student’s t test for independent
samples (two-tailed), and analysis of variance, using MS-
Office 2000 Excel software for PC and Sigma Stat version
2.03 (SPSS). Genotype (ERα −/− versus ERα +/+) and E2
status (OVX, Intact, E2-6, and E2-8) were the grouping
variables. Correlations between parameters were analyzed
using simple linear regression. Probability values at α<0.05
identified all statistically significant comparisons.
Results
Plasma Estradiol We determined plasma estradiol levels in
study mice. We successfully achieved the desired hormonal
status in all of the mice (Fig. 1a). OVX reduced circulating
plasma E2 to very low levels in ERα−/− and ERα+/+ mice.
E2 levels in intact ERα−/− mice were more than twice
those of intact ERα+/+ mice (p<0.05), consistent with the
previously reported ER-dependent functional estrogen
insensitivity of ERα−/− mice [42]. Plasma E2 in exogenous
E2-replaced ERα−/− and ERα+/+ mice were at or above
peak estrus levels, previously reported necessary for
physiologic atheromatous plaque reduction [30–32]. With
E2 replacement, female mice have been previously reported
to develop carcinoma of the cervix and urinary tract and
reproductive tract pathology [43]. None of our study mice
developed cervical carcinoma with E2. However, three mice
developed endometritis, hydronephrosis, and bladder en-
largement unassociated with infection. These mice were
excluded from subsequent analysis.
Uterine weights were measured to functionally assess in
vivo E2 action in our system (Fig. 1b). In ERα+/+ mice, the
very small, atrophic uteri of E2-deficient OVX female mice
confirmed the absence of estrogenic stimulation. ERα+/+
mice with endogenous E2 had significantly (p<0.01) larger
uteri than OVX females. Uterine weights of OVX ERα+/+
female mice replaced with exogenous E2-6 and E2-8 were
over 8-fold larger than OVX ERα+/+ females (p<0.05) and
4-fold larger than intact ERα+/+ mice (p<0.05). As
expected, in ERα−/− mice, uteri were consistently small
and did not significantly enlarge with E2 treatment.
Although E2 has reported effects on body weight in humans
and several animal species [44, 45], there were no
significant differences in body weight between ERα−/−
and ERα+/+ mice in our different treatment groups and
experimental time points (data not shown).
Plasma Lipids Figure 2 summarizes fasting plasma lipids
for total cholesterol, triglycerides, and high-density lipopro-
tein cholesterol for OVX, intact, and E2-replaced ERα−/−
and ERα+/+ female mice while on the atherogenic diet. TC
was lower at baseline in ERα+/+ mice than in ERα−/− mice
(73±11 mg/dl versus 104±5 mg/dl, respectively, p=ns).
Compared to baseline, after 4 months on the atherogenic
diet, fasting TC increased significantly (p<0.05) in OVX,
endogenous E2, and exogenous E2-6 ERα−/− and ERα+/+
mice (32%, 28%, and 30% versus 55%, 58%, and 55% for
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Fig. 1 a Plasma estradiol levels in ERα−/− and ERα+/+ female mice.
Levels of plasma 17β-estradiol (pg/ml; mean±SEM) in ERα−/− and
ERα+/+ female study mice are shown for ovariectomized (OVX, n=
14–15), intact (n=6–10), and ovariectomized replaced with estradiol
pellets designed to deliver 6μg/day (E2-6; n=10–12) and 8μg/day
(E2-8; n=8–13). Statistically significant (p<0.05) and non-significant
(ns) comparisons are shown for each genotype. There were no
significant differences for treatment group comparisons between
genotypes. b Uterine weights in ERα−/− and ERα+/+ female mice.
Uterine weights (g; mean±SEM) in ERα−/− and ERα+/+ female
study mice are shown for ovariectomized (OVX, n=4–6), intact (n=
5–7), and ovariectomized replaced with estradiol pellets designed to
deliver 6μg/day (E2-6; n=13–14) and 8μg/day (E2-8; n=6–14).
Statistically significant (p<0.01) and non-significant (ns) comparisons
are shown for each genotype. In addition, there were significant
differences (p<0.01) for uterine weight comparisons between ERα+/+
E2-6 and E2-8 and all ERα−/− treatment groups
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comparisons between genotypes). However, the atherogenic
diet-associated increase in TC in ERα−/− and ERα+/+ mice
was not affected by estrogen treatments in any of the study
groups, except for a significant (p<0.05) reduction in TC
with exogenous E2-8 only observed in both ERα−/− and
ERα+/+ mice.
In addition, TC levels on the atherogenic diet in OVX and
intact ERα+/+ mice did not correlate with lesion area and
correlated poorly with lesion area in exogenous E2-6
ERα+/+ mice (r=0.56; p=ns). However, in ERα+/+ mice,
the reduction in TC with exogenous E2-8 correlated strongly
with reduction in fatty streak size (r=0.83; p<0.05). In
ERα−/− mice, aortic lesion area did not correlate with TC in
any of the treatment groups. Thus, with the sole exception of
E2-8 in ERα+/+ mice, the dramatic reduction in lesion size
with E2 (endogenous or exogenous) in ERα−/− and ERα+/+
mice was not a consequence of an estrogen-mediated
reduction in TC levels.
There were no significant differences in baseline fasting
plasma TG levels between ERα−/− and ERα+/+ female
mice (75±6 and 81±13 mg/dl, respectively). While on the
atherogenic diet, fasting levels of plasma TG increased
significantly (p<0.05) in all E2 mouse groups, compared to
baseline or OVX (Fig. 2). However, increases in TG did not
correlated with lesion formation in any of the treatment
groups or genotypes.
Fasting levels of HDL-C were similar at baseline in
ERα−/− and ERα+/+ mice (13±2 and 17±4 mg/dl,
respectively). Compared to baseline, HDL levels tended to
be significantly greater in hormone replaced ERα−/− mice
than ERα+/+ mice. However, there were no significant
changes in HDL-C levels between treatment groups in
ERα+/+ mice on the atherogenic diet (Fig. 2). Furthermore,
there was no correlation between lesion area and HDL-C
levels in either genotype.
Lesion Area, Number, and Distribution ERα−/− and
ERα+/+ mice developed aortic lesions typical of fatty
streaks [38]. The fatty-streak lesion area (averaged through-
out the period on the atherogenic diet) for all treatment
groups is summarized in Fig. 3. Endogenous and exoge-
nous E2 were both very effective in inhibiting early lesion
formation. In both ERα−/− and ERα+/+ female mice,
endogenous E2 in mice with intact ovarian function and
exogenous E2 in estrogen-replaced OVX mice significantly
reduced lesion area compared with E2-deficient OVX mice.
Compared to OVX, lesions in mice with endogenous E2
were 64% and 55% smaller in ERα−/− and ERα+/+ mice,
respectively (p<0.001). In addition, following exogenous
E2 replacement, lesions were more than 90% smaller (p<
0.001) in both ERα−/− and ERα+/+ mice compared to
OVX mice. No significant difference in lesions was
observed between the two doses of exogenous estradiol
(E2-6 and E2-8) in ERα−/− or ERα+/+ mice. In addition,
the rate at which lesions developed over time appeared to
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Fig. 2 Plasma lipid levels in ERα−/− and ERα+/+ female mice.
Fasting lipid levels (mg/dl; mean±SEM) for total cholesterol (TC),
triglyceride (TG), and high-density lipoprotein (HDL) were deter-
mined in non-pooled plasma of ERα−/− (n=50 samples for each lipid)
and ERα+/+ (n=49 samples for each lipid) female mice on the
atherogenic diet for animals ovariectomized (OVX), intact, and
ovariectomized replaced with estradiol pellets designed to deliver
6μg/day (E2-6) and 8μg/day (E2-8). *p<0.05 versus lipid baseline
values (not shown, see text) prior to cholesterol feeding for each
genotype; **p<0.05 versus TC in other treatment groups for a given
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Fig. 3 Early lesion formation in ERα+/+ and ERα−/− female mice.
Lesion area (μm
2±SEM) of early atherosclerotic fatty streaks in the
aortas of ERα−/− (n=80) and ERα+/+ female mice (n=77) was
measured at baseline and 2 and 4 months of cholesterol feeding (n=
5–7 mice each per genotype, treatment group, and time point). Lesion
area is shown for mice ovariectomized (OVX), intact, and ovariecto-
mized replaced with estradiol pellets designed to deliver 6μg/day
(E2-6) and 8μg/day (E2-8). Data are mean±SEM lesion area (in μm
2).
*p<0.001 compared to the indicated treatment groups for a given
genotype
J. of Cardiovasc. Trans. Res. (2009) 2:289–299 293decline with increasing estrogenic action in both ERα−/−
and ERα+/+ mice but did not differ between the two
genotypes (data not shown).
For each of the E2 treatment groups, representative
histological lesions of female ERα−/− and ERα+/+ mice
after 4 months on the atherogenic diet are shown (Fig. 4).
Early atherosclerotic lesions were present in the intimal layer
of aortas of both ERα−/− and ERα+/+ mice as early as
2 months on the atherogenic diet, with more extensive
lesions developing over the 4 months of the study. Lesions
were distinguished by lipid infiltration into the vessel wall
and the presence of fatty streaks and did not have character-
istics of advanced lesions, confirming our model of early
atherosclerosis. Compared to endogenous and exogenous E2,
OVX ERα−/− and ERα+/+ mice had early lesions that were
more extensive and lipid rich and with larger deposits of
intra- and extra-cellular lipid. Lesions in ERα−/− and
ERα+/+ endogenous E2 mice had less lipid deposits than
OVX mice but more fatty streaking of the sub-endothelium
than exogenous E2 mice. Lesion formation was essentially
absent in mice replaced with exogenous E2.
We also characterized early lesions by quantity and
segment location in the aorta. The segmental distribution of
early lesions in aortas of ERα−/− (n=51, 48, 54, and 54
total segments for OVX, intact, E2-6, and E2-8, respective-
ly) and ERα+/+ mice (n=51, 51, 51, and 54 total segments
for OVX, intact, E2-6, and E2-8, respectively) is shown in
Fig. 5. All mice showed predilection for early lesion
formation in the proximal aortic segment, with 83–100%
of all early lesions localized to this region of the aorta. The
mid aorta contained 2–18% of early lesions, whereas <3%
of early lesions were in the distal aorta. Differences in
distribution of lesions were significant (p<0.01) between
segments (proximal versus mid versus distal aorta), and
compared to endogenous or exogenous E2, there was
significantly greater (~4-fold) proximal distribution of
lesions in OVX mice. However, lesion distribution was
not significantly affected by ERα status.
The number of lesions in aortas of exogenous (E2-6 and
E2-8) ERα−/− mice was significantly lower (p<0.05) than
in aortas of OVX ERα−/− mice. In ERα−/− mice, the mean
number of lesions in endogenous E2,E 2-6, and E2-8 mice
was 12±5, 8±2, and 10±2, respectively, compared to a
mean of 41±7 lesions in the aortas of OVX mice (p<0.05).
In ERα+/+ mice, a similar pattern was observed with
α +/+ α -/-  
OVX 
Intact 
E2-8
E2-6
Baseline 
ER ER 
Fig. 4 Representative cross sections of lesions from the aortas of
ERα−/− And ERα+/+ mice. Histochemistry of examples of represen-
tative cross sections (10μm) of lesions from the proximal aorta of
cholesterol fed (4 months) ERα−/− (right panel) and ERα+/+ (left
panel) female mice for the following experimental groups: ovariecto-
mized (OVX), ovaries intact, and ovariectomized replaced with
estradiol pellets designed to deliver 6μg/day (E2-6) and 8μg/day
(E2-8). The vessels have been stained for lipid with Oil-red-O and
counterstained with Gill’s Hematoxylin. A normal vessel prior to the
initiation of cholesterol feeding, baseline, is shown for comparison.
The representative images (×20 magnification) demonstrate red-
staining subintimal lipid deposits and fatty streaks. Cross sections
are oriented with the lumen to the right and the adventitial surface to
the left of each image. Size markers=20μm
b
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mice.
Relationship of Plasma Estradiol and Lesions In our
system, early lesion formation was inversely correlated
with plasma estradiol levels in both ERα−/− and ERα+/+
mice. This relationship is demonstrated in Fig. 6.As t e p -
wise reduction in lesion size was observed with a rise in
plasma estradiol, and a converse step-wise increase in
lesion size was seen with a drop in plasma estradiol. OVX
animals had a mean plasma estradiol of only 13 pg/ml (we
assume that the residual measurable estradiol in OVX
mice is due to adrenal sex steroid production and
conversion to estradiol) and the greatest extent of lesions.
Intact mice with endogenous E2, in which mean plasma
estradiol levels were 58 pg/ml, demonstrated nearly 60%
reduction in lesion size (p<0.05). As expected, intact
ERα−/− females had relatively greater endogenous E2
levels than intact ERα +/+ mice due to their relative
insensitivity to estrogen. However, the differences in
endogenous E2 levels between these mice were relatively
small and not sufficient to result in significant differences
in aortic lesions in our studies. However, with higher
plasma estradiol levels (mean >247 pg/ml attained in
exogenous E2 mice), lesion development was essentially
eliminated compared to endogenous E2 and OVX mice
(<0.05). The inverse relationship between mean serum
estradiol and mean lesion area was unaffected by ERα
status as it did not significantly differ between the two
ERα genotypes.
Discussion
The important new finding of our studies is that protection
from development of early atherosclerotic lesions (fatty
streaks) is dependent on estrogen but independent of the
ERα. In addition, estrogen atheroprotection was estrogen-
level dependent, with greater atheroprotection offered by
exogenous estrogen compared to endogenous estrogen and
loss of atheroprotection with ovariectomy.
Atheroprotection by E2 in atherogenic transgenic mouse
models with targeted inactivation of the low-density
lipoprotein receptor [32] and apolipoprotein E [30, 31]
has been demonstrated. In these models, mice spontane-
ously develop advanced atherosclerosis. In a combined
ApoE/ERα deletion model [33], ERα was reported to be a
major mediator of E2 protection in advanced atherosclerotic
lesions. However, whether the same occurs in early-stage
lesions is unknown. In this paper, we demonstrate several
novel findings: (1) E2 inhibits and delays the development
of early lesions by ERα-independent mechanisms, as there
was no significant interaction between ERα genotype and
hormone treatment or hormone status. (2) There was an
estrogen concentration-dependent response to atheroprotec-
tion. And (3) Endogenous and exogenous E2 are both
highly, though not equally, effective in attenuating aortic
lesion development and progression. In our model, inhibi-
tion of early lesions using exogenous E2 in ovariectomized
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(and thus endogenous E2 levels) untouched. This was
somewhat surprising since the dosage used was chosen to
obtain blood E2 levels similar to those at peak estrous,
though actual serum E2 levels attained were at times higher.
However, we do not think that this is the reason that
inhibition of early lesions using exogenous E2 therapy in
ovariectomized animals was more effective at inhibiting
early lesion formation than endogenous E2. A more likely
possibility to consider is that cycling estrogen levels may
attenuate the growth inhibitory effect of endogenous E2,i n
contrast to continuous therapy in our model.
Our findings also extend recent observations reported in
ApoE KO mice in which E2 treatment failed to reduce
aortic lesions in ApoE-deficient mice also lacking ERα
[33]. We postulate that the differences between our findings
and previous are due to two principal factors: (a) the
difference in the animal model used and (b) the differences
in estradiol effect in early- versus late-stage atherosclerosis.
In the previous report, the experimental strain used was the
heterozygous ERα deletion on the atherogenic ApoE null
transgenic mouse background. In contrast, the current study
used ERα-Neo null mice on a mixed 129/J and C57Bl/6J
background. Such mixed background mice are relatively
protected from atherosclerosis and thus, a cholesterol-
containing diet was used to induce aortic fatty streaks that
did not progress to more mature atheroma. We took
advantage of this model to specifically study E2 and ERα
effects on early-stage disease. Secondly, the current study
examined the early stages of atherosclerosis, whereas the
previous report examined more advanced lesions of
atherosclerosis. The differential effects of E2 treatment on
early-stage atherosclerosis as opposed to the more advanced
stages and how ERα is associated with one but not the
other are very important observations and distinctions with
keen relevance to better understanding atherosclerotic
cardiovascular disease. Sex steroid hormones are critical
determinants of cardiovascular sex differences. Moreover,
the effects of estrogens on the blood vessel wall depend
upon the extent and complexity of atherosclerotic disease
present at the time hormone therapy is initiated. As
atherosclerosis evolves, the early vascular protective mech-
anisms of estrogen (e.g., increased NO and cyclooxygense
2 and decreased TNF-α, cell adhesion molecules, LDL
oxidation/binding, platelet activation, and vascular smooth
muscle cell proliferation) recede and are replaced by
estrogen responses that may be deleterious (decrease in
ER function/expression and vasodilation and increase in
inflammatory activation and plaque instability). These
events have recently been comprehensively reviewed by
Turgeon et al. [46], Clarkson [47], and Manson [48]. Thus,
it is becoming increasingly clear that the pleiotropic effects
of hormone therapy on the vascular system and cells differ,
depending not only on hormone status, but also importantly
on the stage of atherosclerosis in the underlying blood
vessel.
We also examined whether the atheroprotective effects
of E2 on early atherosclerosis were lipid mediated.
However, the extent of atheroprotection attributable to E2
in our study and previous studies [30–33] is clearly greater
than can be accounted for by changes in lipid parameters
alone. In LDL-R−/− mice [32], exogenous E2, but not
endogenous E2, lowers cholesterol. In the ERα−/− and
ERα+/+ mice, lipid levels at baseline and following an
atherogenic diet were similar to those previously published
for atherosclerosis-susceptible mouse strains [38]a n d
concur with those reported in ApoE-deficient mice, where
only high doses of exogenous E2 reduced plasma choles-
terol [30]. However, the protective effects of endogenous
and exogenous E2 against fatty-streak formation in our
studies were not correlated with plasma levels of TC, TG,
or HDL-C. Thus, in our model, the traditional factors that
promote lesion formation, such as a high-fat diet and high
plasma cholesterol, did not interact with ERα genotype as
the changes in serum lipoproteins were independent of ERα
expression and occurred in both ERα−/− and +/+ female
mice.
Our studies had some limitations. The ERα-deficient
mouse used (ERα-Neo KO) is not fully null [35, 49, 50]. In
this mouse, the ERα gene was disrupted by the insertion of
the neomycin gene into the first coding exon, resulting in
deficiency of the full-length wild-type ERα protein [34].
This approach also results in the expression of two
alternatively spliced transcripts of the disrupted ERα gene,
E1 and E2 [35], and the expression of two variant ERα
proteins (only one of them found in the aorta) [35, 49]. This
alternative ERα protein has residual low-level, high-
affinity, estradiol-binding activity [35, 36] but lacks the
specificity to be from either ERα or ERβ (Liu and Lubahn,
unpublished data). This variant also has some estrogen-
dependent transcriptional activity [35, 49, 50]—ERα
transcriptional activity is mediated through two activation
functions, AF1 and AF2, whose activity is tightly regulated
in a cell-specific manner through yet unknown processes.
More recently, mice completely deficient of the ERα gene
by excision of exon 2 (ERα-Δ2KO) [51] resulted in the
complete abrogation of an estradiol effect [49]. Although
our studies used the ERα Neo KO model, the results
presented clearly indicate that any residual activity of the
variant of ERα present in the aorta of this mouse model is
not sufficient to protect against atherosclerosis in female
mice, indicating that the expression of the full-length ERα
is not required and that ERα transcriptional activity
mediated through the AF transactivation function is
dispensable in protection against fatty-streak formation in
the vessel wall.
296 J. of Cardiovasc. Trans. Res. (2009) 2:289–299Although our findings indicate that E2 protects against
the development of atherosclerosis by an ERα- and lipid-
independent mechanism, we cannot conclude that the early
atheroprotective effects of E2 occurred entirely via non-
receptor-mediated pathways. In C57BL/6J mice, E2 pre-
vents the vascular injury response to carotid artery
denudation independent of ERα [52], perhaps proceeding
via the ERβ [53]. Although the response to vascular injury
differs from that of the atherosclerotic response to high fat
feeding, a mechanistic role for ERβ seems unlikely in our
system as the ERβ does not appear to be involved in early
stages of atherosclerosis development [6]. Estrogen recep-
tor ERβ localized to the vascular intima is correlated with
coronary calcification and thus more advanced atheroscle-
rosis in pre- and postmenopausal women [54], suggesting a
role for this ER subtype in more advanced vascular disease.
Recently, however, heat shock protein (HSP) 27, an ERβ-
associated protein, was demonstrated to have attenuated
expression in coronary atherosclerosis and to modulate
estrogen signaling in minimally diseased arteries [55].
Thus, in our system, vascular protective effects mediated
by ERβ receptor, its isoforms [56], an as yet uncharac-
terized ER, HSPs, or other factors cannot be excluded and
remain the work for future studies. Lastly, ERα-o rE R β-
independent effects of E2 have been demonstrated for
catechol estrogens (estrogens converted to catechol estro-
gens via oxidation) where inhibition of cell growth by E2 is
independent from ERs [57].
Furthermore, in clinical studies, the common estrogen
receptor-alpha (ER-alpha) IVS1-401 C/C genotype poly-
morphism identifies a group of women (approximately
20%) who have augmented response to hormone therapy.
This has been demonstrated on levels of HDL cholesterol
and intermediate cardiovascular risk markers, such as E-
selectin [58, 59]. Although the impact of this polymorphism
on ERα transcription and other estrogen-sensitive interme-
diate and clinical end points has not yet been established,
the augmented effects of ER polymorphisms on hormone
therapy regulation of lipids and other vascular mediators
may be additional possible mechanisms by which ER
polymorphisms might influence estrogen action in early
atheroprotection. Thus, the implications of differing exper-
imental results in various genetic models as extrapolations
to human disease suggests that a polygenomic approach
will be needed to fully understand whether exogenous
estrogen treatments will be appropriate for all women and
the timing of this treatment in relationship to atherosclerosis
development.
In summary, this study addresses the atheroprotective
role of estradiol that is uncoupled to that of the ERα and
whether the mechanism of action of estradiol in atheropro-
tection is ERα dependent, or not, in early-stage lesions. Our
findings demonstrate that, in early lesions of atherosclero-
sis, the mechanism of atheroprotection is estradiol-mediated
and not dependent on the extent of hyperlipidemia, a
reduction in serum lipids by estrogen, or on the presence or
absence of the ERα. Our findings are important and
provide new clues to the stage of vascular atherosclerosis
at which estradiol and ERα protection occurs. Specifically,
our observations establish that both endogenous and
exogenous E2 retard the development of fatty-streak
formation characteristic of early atherosclerosis in a manner
that is closely tied to estrogen level, yet independent of a
functional ERα. In contrast, and based on prior studies, the
ERα is required for a major part, if not all, of the E2-
mediated reduction in lesion size in plaques with more
advanced lesion characteristics and is a major mediator in
plaque maturation. Furthermore, the inhibitory effects of E2
on atherogenesis appear to be lost once atherosclerotic
lesions are established [60].
In conclusion, our studies contribute to a better under-
standing of ERα-dependent and -independent mechanisms
of E2 atheroprotection, linked to an emerging concept
coupling estrogen action to the timing of its initiation in
relationship to critical periods in the stages of atherogen-
esis. This knowledge is potentially very important, as one
of the most critical areas of new focus in this field is
understanding the molecular and phenotypic interface of
estrogens with their receptors in the vascular wall vis-à-vis
the stage(s) of atherosclerosis. A better understanding of
this system may lead to a better understanding of how to
optimize and when to target hormone therapies for
cardiovascular disease protection in women.
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